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Abstract
Objective: The objective of this selective Evidence Based Medicine (EBM) review is to
determine whether or not “Is Brimonidine Tartrate gel 0.5% effective in reducing facial erythema
of Rosacea?”
Study Design: Review of two randomized controlled trials (RCT), and one 1-year longitudinal
open-label study.
Data Sources: All studies were published in peer-reviewed journals found via the use of PubMed
or Medline.
Outcomes Measured: Patients were divided into two groups: those who received the Brimonidine
Tartrate gel and those who received the vehicle (placebo) gel. Efficacy of Brimonidine tartrate
gel was compared to the efficacy of the vehicle gel. Outcomes were measured at baseline and at
various intervals post treatment using Clinician’s Erythema Assessment (CEA) and Patient’s
Self-Assessment (PSA) scales. Both scales were designed as tools for evaluation of erythema. In
the 1-year open label study, inflammatory lesion counts and telangiectasia were also evaluated to
determine the long-term efficacy of the drug. Additionally, in this study, the subjects were asked
to complete a questionnaire regarding the impact of rosacea on their social life at various points
during the study.
Results: In both RCT, (Fowler – 2011 and Fowler – 2013) results of Brimonidine tartrate gel
versus Vehicle gel reached statistical significance and proved to be an effective form of
treatment in patients with facial erythema of Rosacea (p < 0.001 and p<.05 respectively). In the
open-label study, the effects measured showed that Brimonidine tartrate gel was more effective
than the vehicle gel for long-term treatment of moderate to severe facial erythema of Rosacea
even in the presence of other therapies being used for inflammatory lesions caused by rosacea.
Also, the study showed a decrease in the number of inflammatory lesions and telangiectasias
throughout the study. In addition, this study also showed significant improvement in quality of
social life as reported by patients by completing a questionnaire.
Conclusions: Both RCT and one-year open label studies included in this review indicate that
Brimonidine Tartrate gel 0.5% is an effective treatment for facial erythema of Rosacea in regards
to quality of life and self-confidence due to the appearance.
Keywords: Brimonidine Tartate gel, Rosacea, Facial Erythema
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INTRODUCTION
Rosacea is a very common and chronic dermatologic condition. It is characterized by
flare-ups and remissions of persistent flushing, redness, irritation as well as visible blood vessels.
The areas commonly affected by this condition include forehead, chin, cheeks and nose. It may
also involve the ears, scalp or the neck. If left untreated, it may cause small-red bumps filled with
pus. In severe cases, nose may become bumpy and swell up due to excess tissue – a condition
known as rhinophyma. Since the outbreak of Rosacea can occur at any time unexpectedly, it can
cause psychological and social problems in some patients.1 This paper evaluates two randomized
controlled trials (RCTs) and one 1-year open label study, looking at the effectiveness of
Brimonidine Tartrate gel 0.5% in reducing facial erythema of rosacea, which allows patients to
live a quality of life.
Rosacea affects as many as 16 million people in the United States alone and
approximately 45 million people worldwide.2 In 2014, there were 1,750,000 visits per year for
rosacea and this was due to reasons such as discoloration of the skin, and abnormal
pigmentation.3 The disease typically occurs between the ages of 20 and 50. Even though it can
occur in both men and women, it is more common among women.4 Most people are known to
have fair skin and are known to be Caucasian.2 There is not an exact estimate of the money spent
on treatment of rosacea, however, over $2.16 billion was spent in 2004 worldwide for acne and
rosacea therapeutics.5
Rosacea not only impacts the external appearance of the patient, it has an impact on their
inner aspect as well. It has a psychosocial impact and may cause embarrassment, anxiety and low
self-esteem in some patients.4 According to Millikan and co-authors, many patients have to go
through troublesome of having to deal with rude comments, stares, and misconceptions due to
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effects of rosacea on their appearance.1 Many patients are afraid to eat the food they used to
enjoy the most because of their fear of triggering their flare-up of rosacea.1
The exact cause of rosacea is still unknown; however, it is thought to be due to reduced
ability of the body to diminish inflammation that is caused by environmental factors such as
sunburn.2 Patients are typically advised to avoid specific triggers such as: emotional factors
(stress, fear, anxiety), environmental changes (strong winds, change in humidity), and sun
exposure, all of which can exacerbate their symptoms.2,4 In addition, it is noted that people with
rosacea have excess of Demodex Folliculorum – a mite that lives on everyone’s skin which
might contribute to the development of rosacea.1,2 The skin condition may also occur due to
dysfunction in the vasomotor response causing abnormal dilation of blood vessels of the face.4
Unfortunately, there is no cure or one standard treatment for rosacea. However, there are
many methods available that can control exacerbations of rosacea. There are several types of
topical ointments or oral medications that are currently approved for the treatment of papules and
pustules caused by rosacea and these treatments may include any of the following: azelaic acid,
metronidazole and anti-inflammatory dose of doxycycline. However, currently there is no
medication that has been approved to treat erythema that is caused by rosacea.4,6 Other treatment
therapies that are available for patients with rosacea include: lasers, photodynamic therapy,
pulsed-light therapies, and antibacterial washes.2 Sodium Sulfacetamide is another topical agent
that is known to be effective.2 All the treatment methods described above are effective and are
dependent on the severity of the symptoms caused by rosacea. The results tend to vary from
patient-to-patient and are dependent upon compliance of the patient.1 Brimonidine Tartrate gel
0.5% may be used as a topical medication for the relief of symptoms of Rosacea.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is
Brimonidine Tartrate 0.5% gel is effective in reducing facial erythema of Rosacea?”
METHODS
The investigation looks at two randomized controlled trials (RCTs) and one 1-year open
label study. In order to participate in these studies, a specific selection criteria was used. This
criteria included the following: men or women 18 or older with a clinical diagnosis of rosacea
with moderate to severe erythema. All studies included Brimonidine Tartrate gel 0.5% as the
intervention therapy. All studies used vehicle gel (placebo) as a method of comparison. The
studies also looked at different doses of Brimonidine Tartrate gel and whether they are effective
in treatment for moderate-severe erythema of Rosacea. However, this EBM review focuses on
Brimonidine Tartrate gel 0.5% concentration. The main outcome measured was the reduction in
facial erythema caused by rosacea. In addition, 1-year open label study and Fowler 2011 study
also looked at the effect of Brimonidine Tartrate gel 0.5% to reduce the number of inflammatory
lesions and telangiectasias that were caused by rosacea.
All studies were published in English in peer-reviewed journals that were obtained using
either PubMed or Medline. The key words used to search the articles included “Brimonidine
Tartrate gel”, “Rosacea”, and “Facial Erythema.” All studies were published after the year of
1999 and were selected based on their relevance to the topic and whether or not they included
patient oriented evidence that matters (POEMs). Inclusion criteria for the purpose of this paper
included two randomized controlled studies and one 1-year open-label longitudinal study.
Exclusion criteria included previous cochrane reviews, and systemic reviews submitted by
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previous students. Additional inclusion and exclusion criteria for the individual studies are
included in table 1. The statistics of this study used to evaluate patient outcomes included p
values, RBI, NBI, and NNT. All studies used similar statistics to evaluate the outcomes where pvalue is considered statistically significant if it is less than or equal to 0.05. The demographics of
the studies are included and outlined in Table 1.
Table 1 – Demographics and Characteristics of included studies
Study

Type

# Pts

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria

W/
D

Interventions

Fowler1
(2011)

RCT

53
(Stud
y B)

18-63

Subjects with 3 or
more facial
inflammatory
lesions of
Rosacea.

2
(Stu
dy
B)

During the
first 4 weeks,
subjects
applied gel
once daily in
the morning
No
medication
was applied
during the
follow-up
phase (last 4
weeks).

Fowler2
(2013)

RCT

293
(Stud
y B)

19-78

Men and
Women ≥ 18
years of age,
Moderate to
Severe
erythema
according to
both Clinician’s
Erythema
Assessment
(CEA) and
Patient’s SelfAssessment
(PSA)
Men and
Women ≥ 18
years of age
with a clinical
diagnosis of
Rosacea and
moderate to
severe erythema
according to
both CEA and
PSA

Patients with 3 or
more
inflammatory
lesions of
Rosacea.

10
(Stu
dy
B)

First 4 weeks
(treatment
phase), apply
a thin film of
gel on the
entire face.
No
medication
was applied
during the last
4 week
follow-up
phase.
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Moore3
(2014)

Open
Label
Study

449

19-81

Men and
Women ≥ 18
years of age
with a clinical
diagnosis of
ModerateSevere Rosacea
at both the
screening visit
and baseline
visit.

Dx of Raynaud’s
syndrome, severe
cardiovascular
disease,
cerebral/coronary
insufficiency,
scleroderma.
Treatment with
monoamine
oxidase
inhibitors,
barbiturates or
opiates.

170

Thin film of
topical
Brimoinidine
Tartrate gel
0.5% once
daily in the
morning over
the entire face
for 12
months.

OUTCOMES MEASURED
The main outcome measured in all the selected studies is the effectiveness of
Brimonidine Tartrate gel 0.5% to reduce facial erythema caused by rosacea. In all the articles,
participants’ subjective impression of reduction in facial erythema was measured using the
Patient’s Self-Assessment Scale (PSA). In addition, Clinician’s erythema Assessment scale
(CEA) was also used to determine the impression of the Clinicians’.4,6,7 Both scales were
designed as tools for evaluation of erythema. A one-grade improvement on both scales represents
an effect that is noticeable by both the patient and the investigator and is therefore clinically
relevant, see Table 2. The primary endpoint of the study was the profile of success, defined as a
two-grade improvement on PSA scale.4
Table 2 Clinician’s Erythema Assessment and Patient’s Self-Assessment (Fowler 2011)
Scores

CEA

0, Clear
1, Almost clear
2, Mild

Clear skin, no signs of erythema
Almost clear, slight redness
Mild erythema, definite redness

3, Moderate
4, Severe

Moderate erythema, marked redness
Severe erythema fiery redness

PSA
Clear of unwanted redness
Nearly clear of unwanted redness
Somewhat more redness than I
prefer
More redness than I prefer
Completely unacceptable redness
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In addition to using PSA and CEA scales, both Fowler (2013) and Moore et al., also
measured the decrease in the number of inflammatory lesions and telangiectasia throughout the
course of use of the medication. They measured Telangiectasia using a 5-point scale ranging
from 0 (clear) to 4 (severe). Inflammatory lesion count (sum of papules, pustules, and nodules)
were also done throughout the study. Additionally, in Moore et al., a questionnaire was used to
see the social impact of rosacea on patients’ daily lives. Correspondingly, in Fowler (2013),
Investigator’s Global Assessment (IGA) scale was also utilized to determine the lesion severity
using a 5 point scale ranging from 0 (clear) to 4 (severe).
RESULTS
Fowler (2011) and co-authors, conducted two studies: Study A and Study B. However,
this paper will be focusing on Study B. The duration of this study was 8 weeks (4-week
treatment phase and a 4-week follow-up phase -no medication was applied during this phase).
On days 1, 15 and 29 CEA, PSA and telangiectasis were assessed at 0, 3, 6, 9, and 12 hours.
Inflammatory lesion counts and investigator’s global assessment (IGA) of the lesions were
evaluated at baseline (0 hour on day 1) and at 12 hour on day 29. On day 30, and at weeks 5, 6,
and 8 CEA, PSA, telangiectasia, inflammatory lesion counts and IGA were evaluated. Safety
was evaluated using adverse events, vital signs and intraocular pressure throughout the study.
This EBM review looked at the results of Brimonidine Tartrate gel 0.5% and vehicle gel 3 hours
after the application on Day 29 of the experiment. Study B consisted of 53 patients (11 male 42
female) that were 18 years of age or older who were assigned to the group that was given the
Brimonidine Tartrate gel 0.5% QD and 55 patients (10 male 45 female) were assigned to the
group that was given the vehicle gel QD. Two patients lost to follow-up for the study. At the end
of the treatment phase (day 29), significantly greater success was achieved with Brimonidine
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Tartrate gel 0.5% once daily vs. vehicle once daily (p <.001) (Table 3). The study found that
30% of patients using the Brimonidine Tartrate gel 0.5% had a two-grade improvement in their
facial erythema as compared to 4% of patients on day 29 with the use of vehicle gel. The NNT
was calculated to be 4 (see Table 3), this positive number indicates that 4 people are needed to
treat in order for one person to have a therapeutic response from Brimonidine Tartrate gel 0.5%.
The obtained p-value is less than .001 which is significant and precise. No tachyphylaxis,
telangiectasias, or inflammatory lesions were observed in this study along with no aggravation of
facial erythema during the follow-up phase. The incidence of AEs was similar among all groups
and majority of them were dermatological. During the study, there was no shift or changes in
vitals or intraocular pressure.
Table 3 Efficacy of Brimonidine Tartrate gel 0.5% in treatment of facial erythema of
Rosacea as measured by Fowler 2011
Study
Fowler (2011)

Relative Benefit
Increase (RBI)
6.5

Absolute Benefit
Increase (ABI)
.26

Number Needed to
Treat (NNT)
4 patients

P-value
<.001

Fowler (2013) and co-authors, conducted two studies: Study A and Study B, both were
similar in terms of demographics, disposition and baseline characteristics and both involved 4week treatment phase and a 4-week follow-up phase. The intervention criteria is listed in Table
1. There were 6 visits in each study: screening visit, day 1, 15, and 29 during the treatment phase
which assessed CEA and PSA prior to study drug application and 30 minutes, 3, 6, 9 12 hours
after application and weeks 6 and 8 during the follow-up phase. Telangiectasias, IGA of the
lesion severity and inflammatory lesion counts were also assessed on day 1 before application
and at hour 12 on day 29. During the follow-up phase of the study, CEA, PSA telangiectasia, and
inflammatory lesion count were assessed at each visit. Safety was measured by monitoring
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adverse events, and vital signs throughout the study. This EBM review looked at effect of the
treatment on Day 29, 3 hours after application in study B which consisted of 293 participants.
148 participants (43 male and 105 female) were assigned to the Brimonidine Tartrate gel 0.5%
group and 145 participants (37 male and 108 female) were assigned to the vehicle gel group. 10
participants were lost to follow-up. In this study, significantly greater result was seen with BT
gel 0.5% compared with vehicle gel. 25.4% of patients had an improvement in their facial
erythema after using Brimonidine Tartrate gel as compared to 9.2% of patients using the vehicle
gel. These patients had a 2-grade improvement in both CEA and PSA. The NNT was calculated
to be 7 (see Table 4), this positive number indicates that 7 people are needed to treat in order for
one person to have a therapeutic response from Brimonidine Tartrate gel 0.5%. The obtained pvalue of less than .05 is precise and relatively significant. In both studies, the adverse effects
were mild in intensity and consisted of: worsening of erythema or flushing, and pruritus. No
abnormal vitals, tachyphylaxis were noted and there was no aggravation seen in severity of
telangiectasia or inflammatory lesion counts.
Table 4 Efficacy of Brimonidine Tartrate gel 0.5% in treatment of facial erythema of
rosacea as measured by Fowler 2013
Study

Fowler
(2013)

Control
Event
Rate
(CER)
9.2% =
.092

Experiment
Event Rate
(EER)
25.4% =
.254

Relative
Benefit
Increase
(RBI)
1.76

Absolute
Benefit
Increase
(ABI)
16.2

Number
Needed to
Treat (NNT)

Pvalue

7 patients

<.05

Moore and co-authors conducted a study that was carried out in 27 centers across United
States. The inclusion criteria, exclusion criteria and intervention directions are listed in table 1.
Additionally, there was no restriction seen in terms of number of inflammatory lesions on a
participant’s face. The study contained 8 total visits: screening, day 1, week 1, and month 1, 3, 6,
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9 and 12. Safety was measured at screening, month 1, 6 and 12 by checking vitals, adverse
events, physical exams, laboratory tests and intra-ocular pressure. Telangiectasia, inflammatory
lesion count and CEA and PSA were measured prior to study drug application and 3 hours after
application of the drug. Subjects were also required a complete a questionnaire at baseline,
month 3, 6, 9, and 12. 449 patients took part in this study (113 male and 336 female), however,
279 patients resulted in normal completion time whereas 170 people discontinued from the study
due to adverse events, subject request, protocol violation, pregnancy, etc. This means that only
74.6% of patients had completed the study for atleast 6 months so there was a dropout rate of
25.4% and only 62.1% had completed the study for up to 12 months and there was a dropout rate
of 37.9%. The treatment effect that was measured in this study was mean change from baseline.
According to the results, the mean change from baseline after 1 month period and 0 hours was .5
(large value), mean change from baseline after 1 month period and 3 hours was .2 (small value)
and mean change from baseline in inflammatory lesion count and telangiectasia was .8 (large
value). Over the course of the study, the mean PSA score at hour 0 (prior to daily application of
BT gel 0.5%) reduced gradually from 3.1 on day 1 to 2.6 by the end of the 1st month and
decreased further until the 3rd month and remained stable until month 12. One day 1, after the
first application of topical BT gel 0.5%, the mean PSA decreased from 3.1 at hour 0 to 2.1 at
hour 3. By end of first month, the result of application of Brimonidine tartrate gel after 3 hours
went down to 1.9 from the mean baseline score of 2.1 at day 1. This improvement in erythema of
rosacea as evaluated by patients themselves was also observed at each study visit, and
maintained until the end of study at month 12. Also, the percentage of subjects who considered
that their rosacea inhibited their social life decreased from 29.5% at baseline to 14.2% at month
3, and varied little until the end of the study as measured by the questionnaire that the patients
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were required to fill-out. Overall, this study shows that Brimonidine Tartrate gel 0.5% is an
effective method to reduce facial erythema of rosacea.
DISCUSSION
Rosacea is a very common skin disorder that affects both men and women worldwide. It
comes with persistent flushing and anxiety with low self-esteem in many patients.7 Although,
there are many treatments out there for the treatment of papules, pustules or telangiectasias, there
is no FDA approved medication for the treatment of erythema of rosacea which is a major
complain by many patients.7
Brimonidine Tartrate gel 0.5% is a selective alpha-2 adrenergic receptor agonists which
has a potent vasoconstrictive activity.7 Rosacea deals with vasodilation of the blood vessels,
brimonidine tartrate gel 0.5% works to counteract that effect and causes cutaneous
vasoconstriction.8 Currently, FDA approved Brimonidine (Mirvaso) 0.33% is available for the
treatment of persistent facial erythema of rosacea. The cost of this drug is $431.94 for 0.30g
tube, and it is not available in a generic form.9 However, with the availability of cost reduction
cards, many patients may be eligible to pay $50 or $80 depending on their insurance.10 This
medication is not indicated for inflammatory lesions such as pustules or papules of rosacea. It is
to be used with caution in patients who may have chronic illnesses such as: severe heart disease,
Raynaud phenomenon, orthostatic hypotension, scleroderma and sjogren’s syndrome. It is
unknown whether this drug is safe in pregnancy, in animal studies, it had been shown to be
excreted in breast milk.11
In conclusion, Brimonidine is FDA approved for the treatment of open angle glaucoma.9
The first line medical therapy for open angle glaucoma involves many agents such as beta-

Aggarwal | Rosacea & Brimonidine Tartrate | 11
blockers, sympathomimetics, carbonic anhydrase inhibitors and prostaglandins. Currently, the
alpha 2-agonists, clonidine and now brimonidine have been proven to be powerful inhibitors of
aqueous humor production in order to lower the intraocular pressure (IOP).12 According to
Wilensky, Brimonidine is becoming a first-line therapy for primary open-angle glaucoma and
has the capacity of lowering IOP as comparable to timolol but without the adverse
cardiopulmonary side effects that is caused by timolol.12
CONCLUSION
Brimonidine Tartrate gel 0.5% does appear to reduce facial erythema caused by rosacea.
It has a faster onset when compared to vehicle gel without evidence of rebound, tachyphylaxis or
aggravation of other common clinical signs of rosacea with very limited adverse effects and is
considered safe and well-tolerated.4,6,7 When combined with one of the other therapies: azelaic
acid, metronidazole and oral antibiotic that are used for other clinical signs of rosacea, it can
provide most effective treatment for rosacea.4
Further research studies may be necessary to evaluate long-term efficacy of this drug.
Even though the current studies demonstrated that the long-term side effects of this drug are
limited,4,6,7 supplementary studies are needed to determine the long-term data profile. In further
studies, the inclusion criteria should include patients that have more than 3 inflammatory lesions.
Further studies are needed to aim for insurance approval of this drug. Even though there are
sliding scales available that help lower the cost of the medication, it can still be unaffordable by
some patients. The use of Brimonidine tartrate gel 0.5% to reduce facial erythema of rosacea will
likely to be further explored in the future.
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